Geburtshilfe Frauenheilkd 2020; 80(10): e89
DOI: 10.1055/s-0040-1717201
Fetale Therapie
AGO Mamma State of the Art fortgeschrittenes Mammakarzinom

Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry – comparison of three different prognostic scores

K Riecke
1   Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
,
V Mueller
1   Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
,
T Neunhöffer
2   Frauenärzte am Dom, Mainz, Deutschland
,
R Weide
3   Institut für Versorgungsforschung in der Onkologie, Koblenz, Deutschland
,
M Schmidt
4   Universitätsmedizin Mainz, Mainz, Deutschland
,
TW Park-Simon
5   Medizinische Hochschule Hannover, Hannover, Deutschland
,
C Mundhenke
6   Klinikum Bayreuth GmbH, Bayreuth, Deutschland
,
A Polasik
7   Universität Ulm, Ulm, Deutschland
,
T Hesse
8   Agaplesion Diakonieklinikum Rotenburg, Rotenburg, Deutschland
,
K Lübbe
9   Diakovere Henriettenstift, Breast Center, Hannover, Deutschland
,
E Laakmann
1   Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
,
M Thill
10   Agaplesion Markus Krankenhaus, Frankfurt, Deutschland
,
P Fasching
11   Universitätsklinikum Erlangen, Erlangen, Deutschland
,
C Denkert
12   Institut für Pathologie UKGM – Universitätsklinikum Marburg, Marburg, Deutschland
,
T Fehm
13   Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
,
V Nekljudova
14   German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Deutschland
,
J Rey
14   German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Deutschland
,
S Loibl
14   German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Deutschland
,
I Witzel
1   Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
› Institutsangaben
 

Purpose Several scores have been developed in order to estimate the prognosis of brain metastases (BM) by objective criteria. The original-GPA includes age, Karnofsky-Index (KI), number of BM and extracranial metastases (ECM), the breast-GPA age, KI and tumor-subtype whereas the updated breast-GPA adds subtype and ECM. Aim of this analysis was to validate all three GPA-scores in a large cohort of patients with BM in the Brain Metastases in Breast Cancer (BMBC)-registry.

Methods Retrospective data of 882 patients deriving from the BMBC-registry has been analysed.

Results Median age at BM diagnosis was 57 years. 22.3 % (n = 197) had triple-negative, 33.4 % (n = 295) luminal A, 25.1 % (n = 221) luminal B and 19.2 % (n = 169) HER2-positive breast cancer. Most patients had a good KI (KI > 50 %: 88.4 %, < 50 %: 11.6 %).

All scores were associated with OS. Although the original-GPA had a high sensitivity in predicting 3-months and 12-months-survival (96.2, 92.2 %, score values > vs. ≤3), specificity was low (17.2, 21.8 %), resulting in a low positive predictive value (PPV) (29.7, 62.6 %). Adding more parameters to the score calculation resulted in a higher specificity (53.5 %, 68.7 % for breast-GPA and 35.7, 48.1 % for updated breast-GPA) and PPV (36.1, 75.6 for breast-GPA and 34.2, 69.9 for updated breast-GPA).

Conclusions In this analysis, several clinical parameters and all GPA-scores were significantly associated with OS. All GPA-scores showed only a moderate diagnostic accuracy in predicting OS. Eventhe updated breast-GPA with most of the statistically significant parameters included did not result ina better performance.



Publikationsverlauf

Artikel online veröffentlicht:
07. Oktober 2020

© 2020. Thieme. All rights reserved.
Rüdigerstraße 14, 70469 Stuttgart, Germany